Log in
NASDAQ:ARNA

Arena Pharmaceuticals Stock Forecast, Price & News

$65.68
-0.43 (-0.65 %)
(As of 12/2/2020 12:00 AM ET)
Add
Compare
Today's Range
$65.25
Now: $65.68
$66.34
50-Day Range
$63.85
MA: $75.63
$87.71
52-Week Range
$32.95
Now: $65.68
$90.19
Volume446,454 shs
Average Volume918,049 shs
Market Capitalization$3.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, a Phase IIb/III clinical trial for Crohn's disease, and a Phase IIb clinical trial for atopic dermatitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; and APD418 that is in Phase I clinical trial for acute heart failure. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; and Eisai Co., Ltd. and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Arena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200
Employees320

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$7.87 per share
Book Value$20.11 per share

Profitability

Net Income$397.55 million
Net Margins-5,727.22%

Miscellaneous

Market Cap$3.82 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$65.68
-0.43 (-0.65 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARNA stock has increased by 62.5% and is now trading at $65.68.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Arena Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arena Pharmaceuticals?

Wall Street analysts have given Arena Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arena Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Arena Pharmaceuticals
.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings results on Saturday, November, 14th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.87) by $0.18. The biopharmaceutical company earned $0.02 million during the quarter, compared to the consensus estimate of $1.43 million. Arena Pharmaceuticals had a negative return on equity of 33.17% and a negative net margin of 5,727.22%. Arena Pharmaceuticals's quarterly revenue was down 98.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.46) EPS.
View Arena Pharmaceuticals' earnings history
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

14 analysts have issued 12 month target prices for Arena Pharmaceuticals' stock. Their forecasts range from $62.00 to $120.00. On average, they expect Arena Pharmaceuticals' share price to reach $90.36 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi M.B.A., Pres, CEO & Director (Age 52, Pay $1.23M)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 52, Pay $701.81k)
  • Dr. Preston S. Klassen, Advisor (Age 51, Pay $791.36k)
  • Mr. Robert Lisicki, Exec. VP & Chief Commercial Officer (Age 53, Pay $841.77k)
  • Ms. Laurie D. Stelzer, Exec. VP & CFO (Age 52)
  • Dr. Douglas A. Bakan, Exec. VP of Technical Operations
  • Megan E. Knight, Director of Investor Relations
  • Ms. Joan Schmidt, Exec. VP, Gen. Counsel & Sec. (Age 56)
  • Ms. Suzanne C. Zoumaras, Exec. VP & Chief HR Officer (Age 56)
  • Mr. Steven W. Spector, Consultant (Age 55)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.25%), Lord Abbett & CO. LLC (3.49%), State Street Corp (3.36%), Point72 Asset Management L.P. (2.25%), Great Point Partners LLC (1.71%) and Perceptive Advisors LLC (1.07%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Great Point Partners LLC, State Street Corp, Candriam Luxembourg S.C.A., Victory Capital Management Inc., WINTON GROUP Ltd, and AXA S.A.. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Christopher Cabell, Kevin Robert Lind, Manmeet Singh Soni, Robert Lisicki, Steven W Spector, Tina Susan Nova, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Point72 Asset Management L.P., Great Lakes Advisors LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Sphera Funds Management LTD., Sofinnova Investments Inc., and Assenagon Asset Management S.A..
View insider buying and selling activity for Arena Pharmaceuticals
.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $65.68.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $3.82 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 320 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.